Analytical Data
-
Gene name
KMP-11
- Application
-
Alternative Names
KMP11
-
Species
Trypanosoma cruzi
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9U6Z1
-
Expression Region
1-92aa
-
Molecular Weight
18.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KMP-11, a recombinant protein derived from the parasitic organism Leishmania, has drawn significant attention due to its potential role in vaccine development against leishmaniasis, a disease caused by Leishmania species. This parasitic infection poses a major public health threat in many tropical and subtropical regions, affecting millions of people worldwide. Current treatment options are often limited, with challenges such as toxicity, resistance, and efficacy. Consequently, there is an urgent need for effective vaccines as a proactive approach to prevent the disease. KMP-11, which is part of the Leishmania major genome and is involved in the parasite's pathogenesis, has shown promise in eliciting strong immune responses. Studies have indicated that immunization with KMP-11 can stimulate both humoral and cellular immunity, making it a candidate for further exploration in vaccine formulations. Moreover, the recombinant expression of KMP-11 allows for the production of large quantities of the protein, facilitating extensive immunological studies and the potential development of a cost-effective vaccine. Ongoing research aims to evaluate KMP-11's efficacy in combination with adjuvants to enhance its immunogenicity and to investigate its role in different Leishmania species to address the disease's diverse manifestations. As leishmaniasis continues to represent a major public health issue, the research on KMP-11 and its implications for vaccine development present a significant advancement in the fight against this neglected tropical disease.
